Published in Clin Med Oncol on April 01, 2008
New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst (2000) 133.74
Pemetrexed (ALIMTA), a novel multitargeted antineoplastic agent. Clin Cancer Res (2004) 1.48
A phase I study of pemetrexed, carboplatin, and concurrent radiotherapy in patients with locally advanced or metastatic non-small cell lung or esophageal cancer. Clin Cancer Res (2007) 1.19
Curing patients with locally advanced esophageal cancer: an update on multimodality therapy. Dis Esophagus (2006) 0.94
Definition and classification of cancer cachexia: an international consensus. Lancet Oncol (2011) 7.78
Defective mismatch repair as a predictive marker for lack of efficacy of fluorouracil-based adjuvant therapy in colon cancer. J Clin Oncol (2010) 6.87
Cyclin E and survival in patients with breast cancer. N Engl J Med (2002) 6.44
Cachexia: a new definition. Clin Nutr (2008) 5.49
DNA mismatch repair status and colon cancer recurrence and survival in clinical trials of 5-fluorouracil-based adjuvant therapy. J Natl Cancer Inst (2011) 4.08
Efficacy of pazopanib in progressive, radioiodine-refractory, metastatic differentiated thyroid cancers: results of a phase 2 consortium study. Lancet Oncol (2010) 3.75
Adjuvant radiotherapy and chemotherapy for pancreatic carcinoma: the Mayo Clinic experience (1975-2005). J Clin Oncol (2008) 3.15
Surgical treatment of neuroendocrine metastases to the liver: a plea for resection to increase survival. J Am Coll Surg (2003) 2.88
Factors associated with progression of carcinoid heart disease. N Engl J Med (2003) 2.57
The outcome of combined-modality therapy for stage III non-small-cell lung cancer in the elderly. J Clin Oncol (2003) 2.32
Prognostic significance of defective mismatch repair and BRAF V600E in patients with colon cancer. Clin Cancer Res (2008) 2.32
Obesity is an independent prognostic variable in colon cancer survivors. Clin Cancer Res (2010) 2.18
Professional educational needs for chemotherapy-induced nausea and vomiting (CINV): multinational survey results from 2388 health care providers. Support Care Cancer (2015) 2.11
Preoperative testing before noncardiac surgery: guidelines and recommendations. Am Fam Physician (2013) 2.07
Does dietary counseling improve quality of life in cancer patients? A systematic review and meta-analysis. J Support Oncol (2008) 2.05
Pancreatic endocrine neoplasms: epidemiology and prognosis of pancreatic endocrine tumors. Endocr Relat Cancer (2008) 2.04
Intraepithelial effector (CD3+)/regulatory (FoxP3+) T-cell ratio predicts a clinical outcome of human colon carcinoma. Gastroenterology (2009) 2.04
Current management strategies for ovarian cancer. Mayo Clin Proc (2007) 1.94
Differences in cancer incidence among Indians in Alaska and New Mexico and U.S. Whites, 1993-2002. Cancer Epidemiol Biomarkers Prev (2006) 1.94
Disease-free survival as a surrogate for overall survival in adjuvant trials of gastric cancer: a meta-analysis. J Natl Cancer Inst (2013) 1.90
Percutaneous image-guided radiofrequency ablation of painful metastases involving bone: a multicenter study. J Clin Oncol (2004) 1.90
Painful metastases involving bone: feasibility of percutaneous CT- and US-guided radio-frequency ablation. Radiology (2002) 1.79
Quality of life and symptom burden among long-term lung cancer survivors. J Thorac Oncol (2012) 1.74
Hepatic arterial infusion of a replication-selective oncolytic adenovirus (dl1520): phase II viral, immunologic, and clinical endpoints. Cancer Res (2002) 1.72
Glutamine does not prevent paclitaxel-associated myalgias and arthralgias. J Support Oncol (2004) 1.66
Segmentectomy versus wedge resection for non-small cell lung cancer in high-risk operable patients. Ann Thorac Surg (2013) 1.61
Isolated supraclavicular lymph node metastasis in pancreatic adenocarcinoma: a report of three cases and review of the literature. JOP (2010) 1.60
A combination of esomeprazole and aspirin reduces tissue concentrations of prostaglandin E(2) in patients with Barrett's esophagus. Gastroenterology (2012) 1.58
Muscle wasting in cancer cachexia: clinical implications, diagnosis, and emerging treatment strategies. Annu Rev Med (2011) 1.57
The well-being and personal wellness promotion strategies of medical oncologists in the North Central Cancer Treatment Group. Oncology (2005) 1.57
Phase I and pharmacokinetic study of two different schedules of oxaliplatin, irinotecan, Fluorouracil, and leucovorin in patients with solid tumors. J Clin Oncol (2003) 1.54
Prognosis of carcinoid heart disease: analysis of 200 cases over two decades. Circulation (2005) 1.53
OncoSurge: a strategy for improving resectability with curative intent in metastatic colorectal cancer. J Clin Oncol (2005) 1.52
Complete pathologic response after neoadjuvant chemoradiotherapy for esophageal cancer is associated with enhanced survival. Ann Thorac Surg (2009) 1.51
Worse disease-free survival in never-smokers with ALK+ lung adenocarcinoma. J Thorac Oncol (2012) 1.51
Symptom control trials: a 20-year experience. J Support Oncol (2007) 1.48
Painful metastases involving bone: percutaneous image-guided cryoablation--prospective trial interim analysis. Radiology (2006) 1.46
Gastric surgical adjuvant radiotherapy consensus report: rationale and treatment implementation. Int J Radiat Oncol Biol Phys (2002) 1.41
Comparison of error rates in single-arm versus randomized phase II cancer clinical trials. J Clin Oncol (2010) 1.40
Image-guided ablation of painful metastatic bone tumors: a new and effective approach to a difficult problem. Skeletal Radiol (2005) 1.30
Prognostic impact of FoxP3+ regulatory T cells in relation to CD8+ T lymphocyte density in human colon carcinomas. PLoS One (2012) 1.30
Adjuvant chemotherapy for resected stage II and III colon cancer: comparison of two widely used prognostic calculators. Semin Oncol (2010) 1.28
Body mass index at diagnosis and survival among colon cancer patients enrolled in clinical trials of adjuvant chemotherapy. Cancer (2013) 1.25
Percutaneous image-guided cryoablation of painful metastases involving bone: multicenter trial. Cancer (2012) 1.25
Motivational readiness for physical activity and quality of life in long-term lung cancer survivors. Lung Cancer (2008) 1.23
Impact of overall treatment time on survival and local control in patients with anal cancer: a pooled data analysis of Radiation Therapy Oncology Group trials 87-04 and 98-11. J Clin Oncol (2010) 1.19
The positive impact of a facilitated peer mentoring program on academic skills of women faculty. BMC Med Educ (2012) 1.17
A preoperative serum signature of CEA+/CA125+/CA19-9 ≥ 1000 U/mL indicates poor outcome to pancreatectomy for pancreatic cancer. Int J Cancer (2014) 1.15
Documenting the natural history of patients with resected stage II adenocarcinoma of the colon after random assignment to adjuvant treatment with edrecolomab or observation: results from CALGB 9581. J Clin Oncol (2011) 1.12
Rash from EGFR inhibitors: opportunities and challenges for palliation. Curr Oncol Rep (2008) 1.12
Functional and clinical significance of variants localized to 8q24 in colon cancer. Cancer Epidemiol Biomarkers Prev (2009) 1.11
Prognostic impact of bim, puma, and noxa expression in human colon carcinomas. Clin Cancer Res (2008) 1.08
Search for evidence-based approaches for the prevention and palliation of hand-foot skin reaction (HFSR) caused by the multikinase inhibitors (MKIs). Oncologist (2009) 1.08
Gemcitabine, cisplatin, and radiotherapy for patients with locally advanced pancreatic adenocarcinoma: results of the North Central Cancer Treatment Group Phase II Study N9942. J Clin Oncol (2007) 1.08
Phase 1 trial of flavopiridol combined with cisplatin or carboplatin in patients with advanced malignancies with the assessment of pharmacokinetic and pharmacodynamic end points. Clin Cancer Res (2005) 1.06
Phase I dose escalation study of the PKCι inhibitor aurothiomalate for advanced non-small-cell lung cancer, ovarian cancer, and pancreatic cancer. Anticancer Drugs (2013) 1.04
Stratification of rectal cancer stage for selection of postoperative chemoradiotherapy: current status. Gastrointest Cancer Res (2008) 1.02
Prognostic impact of Beclin 1, p62/sequestosome 1 and LC3 protein expression in colon carcinomas from patients receiving 5-fluorouracil as adjuvant chemotherapy. Cancer Biol Ther (2012) 1.01
A phase I and pharmacologic study of sequences of the proteasome inhibitor, bortezomib (PS-341, Velcade), in combination with paclitaxel and carboplatin in patients with advanced malignancies. Cancer Chemother Pharmacol (2006) 1.01
Does zinc sulfate prevent therapy-induced taste alterations in head and neck cancer patients? Results of phase III double-blind, placebo-controlled trial from the North Central Cancer Treatment Group (N01C4). Int J Radiat Oncol Biol Phys (2007) 1.01
Thymidylate synthase expression in colon carcinomas with microsatellite instability. Clin Cancer Res (2006) 1.00
Biomarker-driven trial in metastatic pancreas cancer: feasibility in a multicenter study of saracatinib, an oral Src inhibitor, in previously treated pancreatic cancer. Cancer Med (2012) 1.00
Alterations in cell proliferation and apoptosis in colon cancers with microsatellite instability. Int J Cancer (2007) 0.99
Somatostatin analogues in the treatment of gastroenteropancreatic neuroendocrine tumors. Mayo Clin Proc (2005) 0.99
The Mayo Clinic experience with multimodality treatment of locally advanced or recurrent colon cancer. Ann Surg Oncol (2002) 0.99
Prognostic factors for limited-stage small cell lung cancer: a study of 284 patients. Lung Cancer (2009) 0.99
Association of obesity with DNA mismatch repair status and clinical outcome in patients with stage II or III colon carcinoma participating in NCCTG and NSABP adjuvant chemotherapy trials. J Clin Oncol (2011) 0.98
Should patients with advanced, incurable cancers ever be sent home with total parenteral nutrition? A single institution's 20-year experience. Cancer (2005) 0.98
Model-based prediction of defective DNA mismatch repair using clinicopathological variables in sporadic colon cancer patients. Cancer (2010) 0.98
A phase I clinical and pharmacokinetic study of CS-682 administered orally in advanced malignant solid tumors. Invest New Drugs (2006) 0.98
Preoperative pulmonary rehabilitation before lung cancer resection: results from two randomized studies. Lung Cancer (2011) 0.97
Oral cancer chemotherapy: the critical interplay between patient education and patient safety. Curr Oncol Rep (2010) 0.97
The value of a symptom cluster of fatigue, dyspnea, and cough in predicting clinical outcomes in lung cancer survivors. J Pain Symptom Manage (2011) 0.96
The value of combined-modality therapy in elderly patients with stage III nonsmall cell lung cancer. Cancer (2007) 0.96
End-of-life hospital costs in cancer patients: do advance directives or routes of hospital admission make a difference? Oncology (2011) 0.95
Gemcitabine and ISIS-2503 for patients with locally advanced or metastatic pancreatic adenocarcinoma: a North Central Cancer Treatment Group phase II trial. J Clin Oncol (2004) 0.95
An international, multicenter phase II trial of bortezomib in patients with hepatocellular carcinoma. Invest New Drugs (2010) 0.94
Fatigue, dyspnea, and cough comprise a persistent symptom cluster up to five years after diagnosis with lung cancer. J Pain Symptom Manage (2011) 0.94
Molecular markers for novel therapies in neuroendocrine (carcinoid) tumors. Endocr Relat Cancer (2010) 0.94
Proapoptotic Bad and Bid protein expression predict survival in stages II and III colon cancers. Clin Cancer Res (2008) 0.93
Medical management of pancreatic neuroendocrine tumors. Am J Gastroenterol (2007) 0.93
Comparative pharmacokinetic study of continuous venous infusion fluorouracil and oral fluorouracil with eniluracil in patients with advanced solid tumors. J Clin Oncol (2002) 0.92
Results of combined-modality therapy for limited-stage small cell lung carcinoma in the elderly. Cancer (2005) 0.92
The cancer anorexia/weight loss syndrome: therapeutic challenges. Curr Oncol Rep (2005) 0.92
Non–small-cell lung cancer in elderly patients: a discussion of treatment options. J Clin Oncol (2014) 0.91
Are 5-7 Days of Folic Acid Supplementation Necessary prior to Pemetrexed? Observations from a Case Series. Case Rep Oncol (2013) 0.89
Nomograms Predict Overall Survival for Patients with Small-Cell Lung Cancer Incorporating Pretreatment Peripheral Blood Markers. J Thorac Oncol (2015) 0.89
Risk factors for significant wound complications following wide resection of extremity soft tissue sarcomas. Clin Orthop Relat Res (2013) 0.89
Phase II study of preoperative pemetrexed, carboplatin, and radiation followed by surgery for locally advanced esophageal cancer and gastroesophageal junction tumors. J Thorac Oncol (2010) 0.89
Hepatic arterial infusion and systemic chemotherapy after multiple metastasectomy in patients with colorectal carcinoma metastatic to the liver: a North Central Cancer Treatment Group (NCCTG) phase II study, 92-46-52. Clin Colorectal Cancer (2011) 0.89
Phase I trial of a pathotropic retroviral vector expressing a cytocidal cyclin G1 construct (Rexin-G) in patients with advanced pancreatic cancer. Mol Ther (2008) 0.88
Safety, pharmacokinetics, and pharmacodynamic properties of oral DEBIO1143 (AT-406) in patients with advanced cancer: results of a first-in-man study. Cancer Chemother Pharmacol (2015) 0.88
Topotecan in patients with advanced neuroendocrine tumors: a phase II study with significant hematologic toxicity. Am J Clin Oncol (2004) 0.87
A mixed-methods feasibility trial of protein kinase C iota inhibition with auranofin in asymptomatic ovarian cancer patients. Oncology (2014) 0.87
Should we recommend surgery to patients with limited small cell carcinoma of the esophagus? J Thorac Oncol (2008) 0.87